Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells
Project/Area Number |
22590497
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | University of Tsukuba |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
ABEI Masato 筑波大学, 医学医療系, 准教授 (20261802)
SUZUKI Hideo 筑波大学, 医学医療系, 准教授 (00400672)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 胃癌 / MDM2 / p53 / siRNA / SIRT1 |
Research Abstract |
Murine double minute 2 (MDM2) is a negative regulator of p53. An MDM2 inhibitor, nutlin-3, stabilized p53 and induced apoptosis in the gastric cell lines with wild-type p53. An in vivo antitumor effect of nutlin-3 alone and its additiveaugmentation by 5-fluorouracil were confirmed in MKN-45 xenograft tumor model. Nutlin-3 showed potent antitumor activity against human gastric cancer cells with wild-type p53 and shows promise as a single agent and in combination with conventional anticancer drugs.
|
Report
(4 results)
Research Products
(6 results)